JP2013526705A - 神経変性疾患のリスクの推移を検出およびプロファイリングする方法 - Google Patents
神経変性疾患のリスクの推移を検出およびプロファイリングする方法 Download PDFInfo
- Publication number
- JP2013526705A JP2013526705A JP2013510115A JP2013510115A JP2013526705A JP 2013526705 A JP2013526705 A JP 2013526705A JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013526705 A JP2013526705 A JP 2013526705A
- Authority
- JP
- Japan
- Prior art keywords
- stem cell
- determining
- neurodegenerative disease
- subject
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 55
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 52
- 210000000130 stem cell Anatomy 0.000 claims abstract description 70
- 238000007069 methylation reaction Methods 0.000 claims abstract description 39
- 230000011987 methylation Effects 0.000 claims abstract description 35
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 13
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
- 108010033040 Histones Proteins 0.000 claims description 25
- 102000006947 Histones Human genes 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 14
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 10
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims description 9
- 101150008375 Pou4f1 gene Proteins 0.000 claims description 9
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 9
- 239000002771 cell marker Substances 0.000 claims description 9
- 230000004069 differentiation Effects 0.000 claims description 9
- -1 TuJ1 Proteins 0.000 claims description 7
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 6
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 229940100601 interleukin-6 Drugs 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 229940064128 l-methylfolate Drugs 0.000 claims description 3
- 235000007635 levomefolic acid Nutrition 0.000 claims description 3
- 239000011578 levomefolic acid Substances 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 description 26
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 15
- 210000001178 neural stem cell Anatomy 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000276 neural tube Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 101150092640 HES1 gene Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100516508 Mus musculus Neurog2 gene Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101000713578 Rattus norvegicus Tubulin beta-3 chain Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000007630 basic procedure Methods 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000001982 neural crest cell Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 101710103773 Histone H2B Proteins 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 102000055601 Nanog Homeobox Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 description 1
- 101710198368 POU domain, class 4, transcription factor 1 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39532110P | 2010-05-11 | 2010-05-11 | |
| US61/395,321 | 2010-05-11 | ||
| PCT/US2011/033387 WO2011142952A1 (en) | 2010-05-11 | 2011-04-21 | Method of detecting and profiling progression of the risk of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526705A true JP2013526705A (ja) | 2013-06-24 |
| JP2013526705A5 JP2013526705A5 (enExample) | 2014-03-27 |
Family
ID=44914644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510115A Pending JP2013526705A (ja) | 2010-05-11 | 2011-04-21 | 神経変性疾患のリスクの推移を検出およびプロファイリングする方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130029998A1 (enExample) |
| EP (1) | EP2569625A4 (enExample) |
| JP (1) | JP2013526705A (enExample) |
| CA (1) | CA2795438A1 (enExample) |
| WO (1) | WO2011142952A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019521953A (ja) * | 2016-04-20 | 2019-08-08 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| JP2021500893A (ja) * | 2017-10-25 | 2021-01-14 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法 |
| US12138282B2 (en) | 2015-06-03 | 2024-11-12 | Aelan Cell Technologies, Inc. | Treatment with an IL-2 based therapy |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7025A (en) * | 1850-01-15 | Buckle | ||
| US11016A (en) * | 1854-06-06 | Method of turning hubs | ||
| WO2009058102A1 (en) * | 2007-11-02 | 2009-05-07 | Agency For Science, Technology And Research | Methods and compounds for preventing and treating a tumour |
| WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
-
2011
- 2011-04-21 WO PCT/US2011/033387 patent/WO2011142952A1/en not_active Ceased
- 2011-04-21 CA CA2795438A patent/CA2795438A1/en not_active Abandoned
- 2011-04-21 JP JP2013510115A patent/JP2013526705A/ja active Pending
- 2011-04-21 EP EP11780997.0A patent/EP2569625A4/en not_active Withdrawn
- 2011-04-21 US US13/640,545 patent/US20130029998A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7025A (en) * | 1850-01-15 | Buckle | ||
| US11016A (en) * | 1854-06-06 | Method of turning hubs | ||
| WO2009058102A1 (en) * | 2007-11-02 | 2009-05-07 | Agency For Science, Technology And Research | Methods and compounds for preventing and treating a tumour |
| WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
Non-Patent Citations (3)
| Title |
|---|
| JPN5013008714; ＳＥＯＮＧ: 'ＨＵＮＴＩＮＧＴＩＮ ＦＡＣＩＬＩＴＡＴＥＳ ＰＯＬＹＣＯＭＢ ＲＥＰＲＥＳＳＩＶＥ ＣＯＭＰＬＥＸ ２' ＨＵＭＡＮ ＭＯＬＥＣＵＬＡＲ ＧＥＮＥＴＩＣＳ Ｖ１９ Ｎ４, 20100215, Ｐ５７３-５８３ * |
| JPN5013008715; ＳＵＢＩＲＡ: 'ＦＬＯＷ ＣＹＴＯＭＥＴＲＩＣ ＡＮＡＬＹＳＩＳ ＯＦ ＣＥＲＥＢＲＯＳＰＩＮＡＬ ＦＬＵＩＤ ＳＡＭＰＬＥＳ ＡＮＤ ＩＴＳ ＵＳＥＦＵＬＮＥＳＳ ＩＮ ＲＯＵＴＩＮＥ ＣＬＩＮＩＣＡＬ ＰＲＡＣＴ' ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＰＡＴＨＯＬＯＧＹ Ｖ１１７ Ｎ６, 200206, Ｐ９５２-９５８, ＡＭＥＲＩＣＡＮ ＳＯＣＩＥＴＹ ＦＯＲ ＣＬＩＮＩＣＡＬ ＰＡＴＨＯＬＯＧＹ * |
| JPN5013008718; ＭＯＲＩＣＩ: ＨＵＮＴＩＮＧＴＯＮ'Ｓ ＯＵＴＲＥＡＣＨ ＰＲＯＪＥＣＴ ＦＯＲ ＥＤＵＣＡＴＩＯＮ， ＡＴ ＳＴＡＮＦＯＲＤ , 20050830 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12138282B2 (en) | 2015-06-03 | 2024-11-12 | Aelan Cell Technologies, Inc. | Treatment with an IL-2 based therapy |
| JP2019521953A (ja) * | 2016-04-20 | 2019-08-08 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| JP6994469B2 (ja) | 2016-04-20 | 2022-02-04 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| JP2024016122A (ja) * | 2016-04-20 | 2024-02-06 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| US12210018B2 (en) | 2016-04-20 | 2025-01-28 | Aelan Cell Technologies, Inc. | Compositions and methods related to the methylation of histone H1.0 protein |
| JP2021500893A (ja) * | 2017-10-25 | 2021-01-14 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法 |
| JP7252953B2 (ja) | 2017-10-25 | 2023-04-05 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2795438A1 (en) | 2011-11-17 |
| US20130029998A1 (en) | 2013-01-31 |
| EP2569625A4 (en) | 2013-12-04 |
| EP2569625A1 (en) | 2013-03-20 |
| WO2011142952A1 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Irwin et al. | Deep clinical and neuropathological phenotyping of P ick disease | |
| Guan et al. | Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease | |
| Barba et al. | Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers | |
| Nijholt et al. | The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies | |
| Caccamo et al. | Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease | |
| Olson et al. | Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements | |
| Regad et al. | The tumor suppressor Pml regulates cell fate in the developing neocortex | |
| Eller et al. | α-Synuclein in Parkinson disease and other neurodegenerative disorders | |
| WO2011094535A2 (en) | Biomarkers of aging for detection and treatment of disorders | |
| JP2013526705A (ja) | 神経変性疾患のリスクの推移を検出およびプロファイリングする方法 | |
| Swenson et al. | Senescence in aging and disorders of the central nervous system | |
| Douglas et al. | Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 colocalize to stress granules resulting in altered RNA and protein levels in a model of neurodegeneration in multiple sclerosis | |
| Ihara et al. | Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease | |
| Sharma et al. | Emerging trends: neurofilament biomarkers in precision neurology | |
| Min et al. | Insulin‐like growth factor I regulates G2/M progression through mammalian target of rapamycin signaling in oligodendrocyte progenitors | |
| EP3894868A1 (en) | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair | |
| Liu et al. | Calcium sensing receptor absence delays postnatal brain development via direct and indirect mechanisms | |
| Liu et al. | A relationship between p27kip1 and Skp2 after adult brain injury: implications for glial proliferation | |
| Sanfilippo et al. | GNG13 is a potential marker of the state of health of Alzheimer’s disease patients’ cerebellum | |
| Teunissen et al. | Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis | |
| Delacourte | Pathological tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration | |
| Iacono et al. | Reduced number of pigmented neurons in the substantia nigra of dystonia patients? Findings from extensive neuropathologic, immunohistochemistry, and quantitative analyses | |
| Costa et al. | Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease | |
| Ferguson et al. | Dynamic expression of the mouse orthologue of the human amyotropic lateral sclerosis associated gene C9orf72 during central nervous system development and neuronal differentiation | |
| US20150025008A1 (en) | Compositions and Methods of Detecting and Treating Neural Tube Defects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140922 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150624 |